Event-Driven Stocks

Verve Therapeutics, Inc.

VERV

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 2 good● 2 warningdetails ↓

Financials

SEC XBRL · annual
 FY24FY23FY22FY21FY20
Revenue—————
Operating income−$228.7M−$223.1M−$165.7M−$87.1M−$40.6M
Net income−$198.7M−$200.1M−$157.4M−$120.3M−$200.1M
Total assets$647.4M$752.7M$679.2M$384.1M$78.4M
Total liabilities$154.0M$153.2M$128.3M$26.8M$17.2M
Equity$493.4M$599.5M$550.9M$357.4M−$63.9M
EPS (diluted)$-2.35$-3.12$-2.91$-4.48$-20.31
Shares out.88.8M83.6M48.6M48.5M2.6M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2024
Operating margin
—
Net margin
—
Return on equity
−40.3%
Return on assets
−30.7%
Return on capital (ROCE)
−37.8%
Liabilities / assets
23.8%
Debt / equity
0.31×
Book value / share
$5.56
Revenue growth (YoY)
—
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2024
Altman Z″ (distress)
2.31grey zone
Accruals / assets
−6.3%clean
Piotroski F-Score
1/7weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
44
/ 100
Profitability 0Growth n/aCatalyst 33Earnings quality 67Financial strength 75

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 2 warning● 2 good
  • Negative operating cash flow
  • Altman Z″ in the grey zone
  • Conservative leverage (liabilities < 50% of assets)
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
Jul 15, 20253.6M1.4-63.3%
Jun 30, 20259.9M1.0-45.0%
Jun 13, 202518.0M5.7-9.3%
May 30, 202519.8M7.3+7.8%
May 15, 202518.4M6.2-0.6%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)